CoChat

Dual Roles of Adiponectin / Acrp30 In Vivo as an Anti-Diabetic and Anti- Atherogenic Adipokine

Yamauchi, Toshimasa, Hara, Kazuo, Kubota, Naoto, Terauchi, Yasuo, Tobe, Kazuyuki, Froguel, Philippe, Nagai, Ryozo, Kadowaki, Takashi · 2003 · Current Drug Targets - Immune, Endocrine & Metabolic Disorders
Cited by 142

The DOI matches its Crossref record.

Abstract

Genome-wide scanning is a powerful tool to identify susceptible chromosome loci, however, individual chromosomal regions still have many candidate genes. Although cDNA microarray analysis provides valuable information for identifying genes involved in pathogenesis, expression levels of many genes are changed. A novel approach for identification of therapeutic targets is the combination of genome-wide scanning and the use of DNA chips, as shown in Fig. (1). Using DNA chips, we screened for secreted molecules, the expressions of which were changed in adipose tissues from mice rendered insulin resistance. Decreased expression of one of these molecules, adiponectin/Acrp30, correlates strongly with insulin resistance. Interestingly, recent genome-wide scans have mapped a susceptibility locus for type 2 diabetes and metabolic syndrome to chromosome 3q27, where adiponectin gene is located. Decreasing serum adiponectin levels are associated with increased risk for type 2 diabetes. Interestingly, adiponectin was decreased in insulin resistant rodent models both of obesity and lipoatrophy, and replenishment of adiponectin ameliorated their insulin resistance. Moreover, adiponectin transgenic mice ameliorated insulin resistance and diabetes Adiponectin knockout mice showed insulin resistance and glucose intolerance. In muscle and liver, adiponectin activated AMP kinase and PPARalpha pathways thereby increasing beta-oxidation of lipids, leading to decreased TG content, which ameliorated insulin resistance under a high-fat diet. Despite similar plasma glucose and lipid levels on an apoE deficient background, adiponectin transgenic apoE deficient mice showed amelioration of atherosclerosis, which was associated with decreased expressions of class A scavenger receptor and tumor necrosis factor alpha. Finally, cDNA encoding adiponectin receptors (AdipoR1 and R2) have been identified by expression cloning, which facilitates the understanding of molecular mechanisms of adiponectin actions and obesity-linked diseases such as diabetes and atherosclerosis and the designing of novel antidiabetic and anti-atherogenic drugs with AdipoR1 and R2 as molecular targets.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/1568008033340090

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 142

Metadata

Authors
Yamauchi, T., Hara, K., Kubota, N., Terauchi, Y., Tobe, K., Froguel, P., Nagai, R., & Kadowaki, T.
Venue
Current Drug Targets - Immune, Endocrine & Metabolic Disorders
Published
2003-12-01
Volume
3
Issue
4
Pages
243-253
ISSN
  • 1568-0088 (ISSN-L)
  • 0000-0000
OpenAlex
W2001892130
Cited by
142
References
0
FWCI
5.61
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dual Roles of Adiponectin / Acrp30 In Vivo as an Anti-Diabetic and Anti- Atherogenic Adipokine. https://app.cochat.ai/papers/10.2174/1568008033340090
The paper
Yamauchi, T., Hara, K., Kubota, N., Terauchi, Y., Tobe, K., Froguel, P., Nagai, R., & Kadowaki, T. (2003). Dual Roles of Adiponectin / Acrp30 In Vivo as an Anti-Diabetic and Anti- Atherogenic Adipokine. Current Drug Targets - Immune, Endocrine & Metabolic Disorders. https://doi.org/10.2174/1568008033340090

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.